Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

NCT04726332 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

52

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Neoplasm Malignant
Epithelial Ovarian Cancer
Triple Negative Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: XL102
DRUG: Fulvestrant
DRUG: Abiraterone
DRUG: Prednisone

Sponsor

Exelixis